Compare IQIYI Inc - ADR (IQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Revvity Inc — how do they compare? IQIYI Inc - ADR trades at $1.34 (market cap $1.30B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 9.9× IQIYI Inc - ADR's market cap, and Revvity Inc pays a 0.24% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| IQ | RVTY | |
|---|---|---|
Market Cap | $1.30B | $12.91B |
Sector | Media | Technology |
52-Week High | $2.79 | $117.75 |
52-Week Low | $0.96 | $82.26 |
Enterprise Value | $2.88B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.325, down 2.57% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two recent quarters. Analyst sentiment is mixed with a 50% buy rating, while news highlights AI platform growth and leadership changes as potential catalysts.
The outlook hinges on IQ's AI-driven content strategy and cost management reversing profitability declines. Risks include intense competition, regulatory pressures in China, and sustained negative cash flow projections for 2026. Upside potential exists if execution improves, but high debt and margin pressures warrant caution for investors.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
